THE Therapeutic Goods Administration (TGA) has published its final decisions around scheduling of nicotine products including e-cigarettes or electronic nicotine delivery systems (ENDS), melatonin, cannabis, vardanefil and many more.
The Department of Health Advisory Committee on Chemicals Scheduling (ACCS) and the Advisory Committee on Medicines Scheduling (ACMS) as well as the Joint Advisory Committee completed their findings in their November 2106 meetings and published them last week.
ENDS gained no relaxation of scheduling, nor did melatonin or vardanefil, each having their current scheduling considered appropriate.
Additional concerns were raised around the scheduling of paracetamol/caffeine combinations, highlighting the sourcing of caffeine from many different foods, drinks and medicines without full awareness on the part of the consumer.
Pentobarbitol also had its scheduling tightened - tga.gov.au for details on these and more.
The above article was sent to subscribers in Pharmacy Daily's issue from 27 Mar 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Mar 17